Bill
H 4494
Prohibits pharmacy benefit managers from retaliating against hospitals and patients using federally-authorized 340B drug discount program to preserve medication affordability for vulnerable populations.
H 4494 would prohibit Pharmacy Benefit Managers (PBMs) from retaliating against or discriminating against hospitals and patients who participate in the 340B drug discount program. The 340B program allows eligible healthcare providers—primarily hospitals serving low-income and uninsured populations—to purchase certain medications at significantly discounted prices. This bill aims to prevent PBMs from penalizing providers or patients for using these federally-authorized discounts.
PBMs act as intermediaries between drug manufacturers, insurers, and pharmacies, controlling which drugs are covered and at what prices. Without protections, PBMs could theoretically retaliate against 340B participants through higher reimbursement rates, formulary restrictions, or patient cost-sharing increases—effectively negating the discount program's benefit. This bill directly impacts healthcare affordability for vulnerable populations and hospital finances, particularly for safety-net institutions serving uninsured and Medicaid patients.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
